Kimberly McHale

Kimberly McHale

Company: Dermavant

Job title: Director of NonClinical Science & Development Program Leader


Kimberly McHale, Ph.D. is the Director of Nonclinical Science for Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. She has several years of drug development experience which spans lead optimization, nonclinical pharmacology, toxicology, clinical development and currently leads the cerdulatinib program at Dermavant Sciences.


Live Discussion & Question Time 2:30 pm

What are the clinical cross-learnings for JAK inhibitor application across both blood-related disorders and immune-mediated diseases? How can we refine clinical trial protocols to include clinically meaningful biomarkers with improved predictability of patient response and clinically meaningful endpoints? In what clinical indications do effective combination regimens that include JAK inhibitors play a role and how…Read more

day: Day One

Designing Translational Medicine Approaches: Topical Cerdulatinib – Case Studies in Atopic Dermatitis & Vitiligo 1:50 pm

Topical cedulatinib and the beneficial pharmacology of dual targeting of JAK and SYK signaling pathways Translational medicine of topical cerdulatinib: case studies in Atopic Dermatitis and vitiligoRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.